- Home
- CAG vs EXAS Comparison
CAG vs EXAS Comparison
Compare CAG & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAG
- EXAS
- Stock Information
- Founded
- CAG 1919
- EXAS 1995
- Country
- CAG United States
- EXAS United States
- Employees
- CAG N/A
- EXAS N/A
- Industry
- CAG Packaged Foods
- EXAS Medical Specialities
- Sector
- CAG Consumer Staples
- EXAS Health Care
- Exchange
- CAG Nasdaq
- EXAS Nasdaq
- Market Cap
- CAG 9.3B
- EXAS 8.6B
- IPO Year
- CAG N/A
- EXAS N/A
- Fundamental
- Price
- CAG $19.69
- EXAS $47.47
- Analyst Decision
- CAG Hold
- EXAS Strong Buy
- Analyst Count
- CAG 11
- EXAS 22
- Target Price
- CAG $21.73
- EXAS $66.43
- AVG Volume (30 Days)
- CAG 10.8M
- EXAS 4.0M
- Earning Date
- CAG 10-01-2025
- EXAS 08-06-2025
- Dividend Yield
- CAG 7.25%
- EXAS N/A
- EPS Growth
- CAG 233.33
- EXAS N/A
- EPS
- CAG 2.40
- EXAS N/A
- Revenue
- CAG $11,612,800,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- CAG N/A
- EXAS $14.61
- Revenue Next Year
- CAG N/A
- EXAS $12.71
- P/E Ratio
- CAG $8.19
- EXAS N/A
- Revenue Growth
- CAG N/A
- EXAS 12.55
- 52 Week Low
- CAG $18.19
- EXAS $38.81
- 52 Week High
- CAG $33.24
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- CAG 55.36
- EXAS 52.00
- Support Level
- CAG $19.01
- EXAS $44.90
- Resistance Level
- CAG $19.66
- EXAS $46.26
- Average True Range (ATR)
- CAG 0.39
- EXAS 1.88
- MACD
- CAG 0.12
- EXAS 0.61
- Stochastic Oscillator
- CAG 92.17
- EXAS 94.03
About CAG ConAgra Brands Inc.
Conagra Brands is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. The company primarily sells through the US retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.